Illumina (NASDAQ:ILMN) Q4 Outperforms: 5% Revenue Rise, 8.3% EPS Beat, Clinical Momentum Drives Outlook

Illumina (NASDAQ:ILMN) reported Q4 CY2025 revenue of $1.16 billion, up 5% year-over-year, and non-GAAP profit of $1.35 per share, 8.3% above estimates. The company’s full-year revenue guidance of $4.55 billion is 3% above analysts’ expectations. Fourth-quarter clinical consumables growth reached 20% outside China, supported by expanded sequencing-based diagnostics and higher data-intensity clinical applications. CEO Jacob Thaysen highlighted ongoing momentum, while CFO Ankur Dhingra cautioned that research and academic demand remain subdued due to funding constraints, contributing to a mixed market reaction. Looking ahead, Illumina projects double-digit to mid-teens growth in clinical consumables, driven by expanding whole-genome approaches in oncology and genetic diseases, and by integrating multi-omics capabilities and the recently acquired Somalogic proteomics platform. The company is managing margin expansion and monitoring the commercial rollout of the NovaSeq X platform, early revenue contributions from the Somalogic acquisition, and regulatory developments in China. The stock closed at $127.11, down from $133.61 pre-earnings.